THE EFFICACY OF INTRAVESICAL BACILLUS CALMETTE-GUERIN IN THE TREATMENT OF INTERSTITIAL CYSTITIS: LONG-TERM FOLLOWUP
Abstract
Purpose:
Interstitial cystitis is a severe debilitating bladder disease characterized by unrelenting pelvic pain and urinary frequency. A prospective, double-blind, placebo controlled study of the use of intravesical bacillus Calmette-Guerin (BCG) in the treatment of interstitial cystitis was recently completed with a mean followup of 8 months. Results demonstrated a 60% BCG response rate, compared to a 27% placebo response rate. We now report the long-term followup results of those patients who received intravesical BCG.
Materials and Methods:
Subjects randomized to receive BCG were followed at routine intervals with questionnaires and voiding diaries identical to those in the blinded study. Adverse events were closely monitored in the treatment and followup phases of the study. Subject baseline values were compared to followup data.
Results:
Of the BCG responders mean followup was 27 months (range 24 to 33), and 8 of 9 (89%) continue to have an excellent response in all parameters measured. The global interstitial cystitis survey improved 70%, daily voids decreased 31%, nocturia improved 54%, mean voided volume increased 61%, pelvic pain decreased 81%, vaginal pain decreased 71%, urgency decreased 71% and dysuria decreased 82%. Overall well-being improved 54% and the Rand-36 quality of life survey overall improved 64%. In 86% of the patients (6 of 7) dyspareunia resolved. Of the initial BCG nonresponders there was no significant difference in interstitial cystitis symptomatology from baseline to last followup, suggesting that BCG does not worsen interstitial cystitis symptoms. No long-term adverse events from BCG were noted.
Conclusions:
Intravesical Tice* Organon Inc., West Orange, New Jersey.
References
- 1 : A rare type of bladder ulcer in women; report of cases. Boston Med. Surg. J.1915; 172: 660. Google Scholar
- 2 : Bacillus calmette-guerin immunotherapy for refractory interstitial cystitis. Urology1994; 43: 121. Google Scholar
- 3 : The efficacy of intravesical Tice strain bacillus calmette-guerin in the treatment of interstitial cystitis: a double-blind, prospective, placebo controlled trial. J. Urol.1997; 157: 2090. Link, Google Scholar
- 4 : Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases workshop on interstitial cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29, 1987. J. Urol.1988; 140: 203. Abstract, Google Scholar
- 5 : KUH Notes. J. Urol.1989; 142: 139. Link, Google Scholar
- 6 : The MOS 36-item short-form health survey (SF-36): I. conceptual framework and item selection. Med. Care1992; 30: 473. Google Scholar
- 7 : Measurement of symptoms of interstitial cystitis. Urol. Clin. N. Amer.1994; 21: 67. Google Scholar
- 8 : A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J. Urol.1993; 150: 845. Link, Google Scholar
- 9 : Evidence of urothelial cell activation in interstitial cystitis. J. Urol.1993; 149: 470. Abstract, Google Scholar
- 10 : Abnormal urothelial HLA-DR expression in interstitial cystitis. Clin. Exp. Immunol.1992; 87: 450. Google Scholar
- 11 : Bladder antibodies in interstitial cystitis. J. Urol.1970; 103: 307. Link, Google Scholar
- 12 : Specific auto-antibodies in interstitial cystitis patients suggest an autoimmune etiology. J. Urol.1996; 155: 431A. part 2, abstract 483. Google Scholar
- 13 : Urine autoantibodies in interstitial cystitis. J. Urol.1997; 157: 1083. Link, Google Scholar
- 14 Ochs, R. L., Muro, Y., Chan, E. K. L., Tan, E. M. and Keck, W. M.: Autoantibodies to DFS70 in patients with interstitial cystitis or atopic dermatitis (abstract). International Research Symposium on Interstitial Cystitis, Washington, D. C., p. 80, 1997. Google Scholar
- 15 : The role of IL-10 in cross-regulation of TH1 and TH2 responses. Immunol. Today1997; 12: A49. Google Scholar
- 16 : Conversion of the CD4+ T cell profile from TH2-dominant type to TH1-dominant type after varicella-zoster virus infection in atopic dermatitis. J. Allergy Clin. Immunol.1997; 100: 274. Google Scholar
- 17 : Interleukin-6 and interstitial cystitis. J. Urol.1994; 152: 869. Link, Google Scholar
- 18 : Urinary interleukin-2 inhibitor and the voiding symptoms in women patients with interstitial cystitis. Sem. Urol.1991; 9: 120. Google Scholar
- 19 : Adjuvants, endocrines and conserved epitopes: factors to consider when designing “therapeutic vaccines”. Int. J. Immunopharmacol.1995; 17: 91. Google Scholar
- 20 : Elevations of cytokines interleukin 1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus calmette-guerin immunotherapy. J. Urol.1990; 144: 59. Abstract, Google Scholar
- 21 : Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J. Clin. Oncol.1996; 14: 1778. Google Scholar
- 22 : Improvement in interstitial cystitis symptom scores during treatment with oral l-arginine. J. Urol.1997; 158: 703. Link, Google Scholar
- 23 : Differential responses to challenge with live and dead mycobacterium bovis bacillus calmette-guerin. J. Immunol.1997; 158: 1742. Google Scholar
From the Department of Urology, William Beaumont Hospital, Royal Oak, Michigan.
